Use of recombinant FVIIa for intraperitoneal coagulopathic bleeding in a septic patient

Current Surgery

Volumn 60, Issue 4, 2003, Pages 423-427

  Holcomb, John B ^a,b   Neville, Holly L ^a   Fischer, Craig F ^a   Hoots, Keith ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Coagulopathy; FVIIa; Pancreatitis; Sepsis

Indexed keywords

ADRENALIN; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; ESTROGEN; FIBRIN; NORADRENALIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; VASOPRESSIN; WARFARIN;

ACUTE HEMORRHAGIC PANCREATITIS; ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CASE REPORT; COMPARTMENT SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DETERIORATION; DISEASE COURSE; DISEASE DURATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG MECHANISM; DRUG SAFETY; DRUG USE; ENDOTHELIUM INJURY; FIBRIN DEPOSITION; HEMOPERITONEUM; HUMAN; KIDNEY FAILURE; LAPAROTOMY; MALE; PATIENT TRANSPORT; RESPIRATORY FAILURE; RETROPERITONEAL HEMORRHAGE; SEPSIS; SYMPTOMATOLOGY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

BLOOD COAGULATION DISORDERS; DEBRIDEMENT; FACTOR VIIA; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; LAPAROTOMY; MALE; MIDDLE AGED; PANCREATITIS, ACUTE NECROTIZING; RISK ASSESSMENT; SEPSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038010106     PISSN: 01497944     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7944(02)00690-6     Document Type: Article

References (56)

1. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis and Haemostasis. 1998;80:773-778.
2. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S107-S111.
3. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion. 2002;42(1):114-124.
4. Holcomb J, Pusateri A, MacPhee M, Hess J. New technologies in hemorrhage control. Curr Opin Crit Care. 1997;3:488-493.
5. Jurlander B, Thim L, Klausen NK, et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost. 2001;27:373-384.
6. Poon MC, d'Oiron R, Hann I, et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol. 2001;38(suppl 12):21-25.
7. Stepinska J, Banaszewski M, Konopka A, Szajewski T. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost. 2002;87:355-356.
8. Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000;26:373-377.
9. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113: 1930-1937.
10. Erhardtsen E, Nony P, Dechavanne M, French P, Boisse JP, Hedner U. The effect of recombinant factor VIIa (Novoseven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinolysis. 1998;9:741-748.
11. Papatheodoridis GV, Chung S, Keshav S, Pasi J, Burroughs AK. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol. 1999;31:747-750.
12. Douri MA, Shafi T, Khudairi DA, et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagulation Fibrinolysis. 2000; 11(suppl 1):S121-S127.
13. White B, Ravi N, McHale J, et al. Successful use of recombinant FVIIA (Novoseven) in the management of intractable post surgical intra-abdominal haemorrhage. Brit J Haematol. 1999;107:677-678.
14. Vlot AJ, Ton E, Mackaay AJ, Kramer MH, Gaillard CA. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med. 2000;108:421-423.
15. Kalicinski P, Kaminski A, Drewniak T. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplantation Proceedings. 1999;31: 378-379.
16. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999;354:1879.
17. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001;51:431-439.
18. Hendriks HGD, Meijer K, Hagenaars A, et al. Reduced transfusion requirements by recombinant Factor VIIa in orthotopic liver transplantation. Transplantation. 2001; 71:402-405.
19. Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol. 2001;114(1): 174-176.
20. Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001;28:405-407.
21. Friederich PW, Geerdink MG, Spataro M, et al. The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis. 2000; 11(suppl 1):S129-S132.
22. O'Neill PA, Bluth M, Gloster ES, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma. 2002;52:400-405.
23. Chuansumrit A, Chantarojanasiri T, Isarangkura P, Teeraratkul S, Hongeng S, Hathirat P. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2000;11(suppl 1):S101-S105.
24. Bradley EL III. Indications for debridement of necrotizing pancreatitis. Pancreas. 1996;13:219-223.
25. Fernandez-del Castillo C, Rattner DW, Makary MA,Mostafavi A, McGrath D, Warshaw AL. Debridement and closed packing for the treatment of necrotizing pancreatitis. Ann Surg. 1998;228:676-684.
26. Tsiotos GG, Luque-de Leon E, Soreide JA, et al. Management of necrotizing pancreatitis by repeated operative necrosectomy using a zipper technique. Am J Surg. 1998; 175:91-98.
27. Le Mee J, Paye F, Sauvanet A, et al. Incidence and reversibility of organ failure in the course of sterile or infected necrotizing pancreatitis. Arch Surg. 2001;136:1386-1390.
28. Bradley EL. Pancreatic abscess. In: Cameron JL, ed. Current. Surgical therapy, 6th ed. St Louis, MO: Mosby; 1998: 502-506.
29. Reed RL, Bracey AW, Hudson JD, Miller TA, Fischer RP. Hypothermia and blood coagulation: dissociation between enzyme activity and clotting factor levels. Circulatory Shock. 1990;32:141-152.
30. Rohrer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. Crit Care Med. 1992;20:1402-1405.
31. Reed RL, Johnson TD, Hudson JD, Fischer RP. The disparity between hypothermic coagulopathy and clotting studies. J Trauma. 1992;33:465-470.
32. Gubler KD, Gentilello LM, Hassantash A, Maier RV. The impact of hypothermia and dilutional coagulopathy. J Trauma. 1994;36:847-851.
33. Gentilello LM, Jurkovich GJ, Stark, MS, Hassantash SA, O'Keefe GE. Is hypothermia in the victim of major trauma protective or harmful? A randomized prospective study. Ann Surg. 1997;226:439-449.
34. Watts DD, Trask A, Soeken K, Perdue P, Dols S, Kaufman K. Hypothermic coagulopathy in trauma: effect of varying levels of hypothermia on enzyme speed, platelet function, and fibrinolytic activity. J Trauma. 1998;44: 846-854.
35. Rapaport SI, Rao LVM. The tissue factor pathway: how it has become a "prima ballerina" Thromb Haemost. 1995; 74:7-17.
36. Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B. Predicting life-threatening coagulopathy in the massively transfused patient: Hypothermia and acidosis revisited. J Trauma. 1997;42:857-862.
37. Tremblay LN, Feliciano DV, Schmidt J, et al. Skin only or silo closure in the critically ill patient with an open abdomen. Am J Surg. 2001;182:670-675.
38. Rotondo MF, Zonies DH. The damage control sequence and underlying logic. Surg Clin North Am. 1997;77:761-777.
39. Shapiro MB, Jenkins DH, Schwab CW, Rotondo MF. Damage control: collective review. J Trauma. 2000;49: 969-978.
40. McNelis J, Marini CP, Jurkiewicz A, et al. Predictive factors associated with the development of abdominal compartment syndrome in the surgical intensive care unit. Arch Surg. 2002;137:133-136.
41. Raeburn CD, Moore EE, Biffl WL, et al. The abdominal compartment syndrome is a morbid complication of postinjury damage control surgery. Am J Surg. 2001;182: 542-546.
42. Martinowitz U, Holcomb JB, Pusateri AE. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma. 2001;50:721-729.
43. Schreiber MA, Holcomb JB, Brundage SI, et al. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma. 2001;51:1233.
44. Lynn M, Jerohmimov I, Johnson EW, et al. Early use of recombinant factor VIIa decreases mortality in experimental hemorrhagic shock-a randomized double blind trial. J Trauma. 2001;50(1):177.
45. Schreiber MA, Holcomb JB, Hedner U, et al. The effect of recombinant factor VIIa on non-coagulopathic pigs with grade V liver injuries. JSR. (accepted)
46. Jewelewicz D, Zaias J, Hensley GT, et al. Use of recomnbinant factor VIIa in a porcine model of uncontrolled hemorrhage is not associated with an increase increased risk of thrombosis. J Trauma. 2002;52(1):197.
47. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury multiple organ failure: a bimodal phenomenon. J Trauma. 1996;40:501-502.
48. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg. 2001;67:377-382.
49. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis. J Trauma. 1999;47:719-723.
50. Vasquez Y, Williams CH, Hardaway RM. Effect of urokinase on disseminated intravascular coagulation. J Appl Physiol. 1998;85:1421-1428.
51. Hardaway RM, Williams CH, Vasquez Y. Disseminated intravascular coagulation in sepsis. Semin Thromb Hemost. 2001;27:577-583.
52. Hedner U, Kisiel W. The use of human factor VIIa in the treatment of two hemophilia patients with high-titer inhibitors. J Clin Invest. 1983;71:1836-1844.
53. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol. 1999;188:180-188.
54. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant factor VII (Novoseven) in a patient with haemophilia A and inhibitor. Thromb Haemost. 1999;82:1775-1776.
55. Hedner U. Reported serious adverse events during the use of rFVIIa. In: Hedner U, ed. Recombinant Factor VIIa. Update on Clinical Experiences. International Workshop on Novoseven, April 24, 1998. Frankfurt, Germany.
56. Roberts HR. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol. 2001;38(suppl 12):48-50.